Amylyx Pharmaceuticals is set to release clinical data from its phase 3 trial evaluating a treatment for hypoglycemia.
Amylyx Pharmaceuticals announced plans to release results from its phase 3 clinical trial assessing a drug candidate targeted at treating hypoglycemia.
Further details regarding the exact timeline of the data release and the specific trial endpoints were not immediately available.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
